501 Clinical PK of XW10172 for Once Nightly Therapy in Patients with Narcolepsy or Sleep Disorders in Neurodegenerative Diseases
Sign Up to like & getrecommendations! Published in 2021 at "Sleep"
DOI: 10.1093/sleep/zsab072.500
Abstract: Patients with narcolepsy and patients with sleep disorders secondary to neurodegenerative diseases have been shown to respond to oxybate. To overcome the limitations of current oxybate therapies, we designed XW10172, a new chemical entity and… read more here.
Keywords: oxybate; sleep disorders; 501 clinical; xw10172 ... See more keywords